STOCK TITAN
  1. Home
  2. News
  3. VTRS

Viatris Inc. - $VTRS STOCK NEWS

Welcome to our dedicated page for Viatris news (Ticker: $VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Viatris's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Viatris's position in the market.

News
Rajiv Malik to Retire as President of Viatris Effective April 1, 2024
Rhea-AI Summary
Viatris President Rajiv Malik to retire in April 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
none
-
News
Viatris Named to 3BL's 100 Best Corporate Citizens of 2023 Ranking
Rhea-AI Summary
Viatris Named to 3BL's 100 Best Corporate Citizens Ranking
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
none
-
News
Viatris to Release Third Quarter 2023 Financial Results on November 7, 2023
Rhea-AI Summary
Viatris Inc. to release Q3 2023 financial results on November 7th.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
earnings
News
Viatris Announces Agreements on Remaining Planned Divestitures; Upon Closing Would Achieve its Original Total Target of a Multiple Above 12x on 2022 Estimated Adjusted EBITDA
Rhea-AI Summary
Viatris announces divestitures of OTC, Women's Healthcare, and API businesses, with total gross proceeds of up to $6.94B and estimated retained value of approximately $1.6B. Retains rights for Viagra®, Dymista®, and select OTC products. Completion expected by H1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.93%
Tags
none
-
News
Viatris Named to TIME's World's Best Companies 2023 List
Rhea-AI Summary
Viatris Inc. named to TIME's World's Best Companies 2023 list and recognized for reduction in emissions intensity. Additional honors include Forbes' World's Best Employers 2022 list and Fortune's Change the World list.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
none
-
News
Viatris Announces U.S. FDA Tentative Approval of a Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), a Once-daily Treatment for Children Living with HIV
Rhea-AI Summary
Viatris receives tentative approval from FDA for a new HIV treatment for pediatric patients. The approval will enhance access to WHO-recommended regimen and improve adherence to HIV treatment in low- and middle-income countries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
none
News
Viatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1]
Rhea-AI Summary
Viatris Inc. (NASDAQ: VTRS) reports total revenues of $3.92 billion, U.S. GAAP net earnings of $264 million, and adjusted EBITDA of $1.31 billion for the quarter. The company reaffirms that full-year total revenues, adjusted EBITDA, and free cash flow are expected to be at the midpoint of 2023 guidance ranges. Viatris also pays down $727 million of debt year to date and remains on track to announce planned divestitures in 2023. The board of directors declares a quarterly dividend of $0.12 per share. Strong results signal the expected beginning of a growth journey.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.87%
Tags
earnings
-
News
Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis
Rhea-AI Summary
Viatris Inc. (NASDAQ: VTRS) announces FDA acceptance of NDA for GA Depot 40 mg, a long-acting glatiramer acetate for RMS treatment, with PDUFA action date of March 8, 2024. Supported by positive Phase III trial results, milestone reflects commitment to addressing MS community needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.87%
Tags
clinical trial
-
News
Viatris Announces Launch of Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the First FDA-Approved Generic Version of Symbicort® for People with Asthma and Chronic Obstructive Pulmonary Disease, in Partnership with Kindeva
Rhea-AI Summary
Viatris Inc. (VTRS) and Kindeva Drug Delivery L.P. launch Breyna™, the first generic version of AstraZeneca's Symbicort® with an Abbreviated New Drug Application (ANDA) approved by the U.S. Food and Drug Administration (FDA). Breyna is indicated for certain patients with asthma or chronic obstructive pulmonary disease (COPD) and will be immediately available in both 80 mcg/4.5 mcg and 160 mcg/4.5 mcg dosage strengths. Viatris has also established a copay program to expand access to Breyna, offering eligible commercially-insured patients reduced out-of-pocket expenses on prescriptions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
partnership
News
Viatris to Report Second Quarter 2023 Financial Results on August 7, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
conferences earnings
Stock VTRS logo
Viatris Inc.

Nasdaq:VTRS

VTRS Rankings

#649 Ranked by Market Cap
#2929 Ranked by Stock Gains
#808 Ranked by Dividends

VTRS Stock Data

14.03B
1.18B
0.35%
83.36%
3.06%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
CANONSBURG

About VTRS

mylan is a global pharmaceutical company committed to setting new standards in healthcare. working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. we offer a growing portfolio of around 1,400 generic pharmaceuticals and several brand medications. in addition, we offer a wide range of antiretroviral therapies, upon which nearly 50% of hiv/aids patients in developing countries depend. we also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in about 145 countries and territories. our workforce of approximately 30,000 people is dedicated to creating better health for a better world, one person at a time. learn more at mylan.com.